Floatz logo

Mutated Human Immunoglobulin G1 Fc Fragment Anti-(Homo Sapiens Igg Receptor Fcrn Large Subunit P51 (Neonatal Fc Receptorfcrn))(37-Tyr(M>Y(32),39-Thr(S>T(34),41-Glu(T>E(36),218-Lys(H>K(213)),219-Phe(N>F(214))(Fc Fragment Of Human Immunoglobulin Heavy Constant Gamma 1)-(6-232)-Peptide, Dimer (6-6':9-9')-Bisdisulfide, Produced In Cho Cells, Glycoform Alfa

Optic Neuritis

Explore 4 assets in Optic Neuritis →
Floatz Rating
CCC53/100
Confidence
Indicative
v0.2
Sponsor
Anastasia Vishnevetsky, MD, MPH
Modality
protein_peptide
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT06453694CT.gov
Efgartigimod for the Treatment of Acute Optic Neuritis
—Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Optic Neuritis

AssetSponsorPhaseRating
Mutated Human Immunoglobulin G1 Fc Fragment Anti-(Homo Sapiens Igg Receptor Fcrn Large Subunit P51 (Neonatal Fc Receptorfcrn))(37-Tyr(M>Y(32),39-Thr(S>T(34),41-Glu(T>E(36),218-Lys(H>K(213)),219-Phe(N>F(214))(Fc Fragment Of Human Immunoglobulin Heavy Constant Gamma 1)-(6-232)-Peptide, Dimer (6-6':9-9')-Bisdisulfide, Produced In Cho Cells, Glycoform Alfa (this asset)Anastasia Vishnevetsky, MD, MPHP2CCC · 53
Interferon ?1 (Human Fibroblast Protein Moiety)MidAmerica Neuroscience Research Foundation at Rowe Neurology InstituteP4BB
FampridineCourtney CasserlyP2/3BB
SimvastatinGlostrup University Hospital, CopenhagenP3B
MethotrexateMidAmerica Neuroscience Research Foundation at Rowe Neurology InstituteP4B
PrednisoneNational Eye Institute (NEI)P3B
PrivosegtorOculisP3B
Erythropoietin AlfaUniversity Eye Hospital, FreiburgP3B
ErythropoietinInstitut fuer anwendungsorientierte Forschung und klinische Studien GmbHP2B

+7 more in the Optic Neuritis cohort

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Mutated Human Immunoglobulin G1 Fc Fragment Anti-(Homo Sapiens Igg Receptor Fcrn Large Subunit P51 (Neonatal Fc Receptorfcrn))(37-Tyr(M>Y(32),39-Thr(S>T(34),41-Glu(T>E(36),218-Lys(H>K(213)),219-Phe(N>F(214))(Fc Fragment Of Human Immunoglobulin Heavy Constant Gamma 1)-(6-232)-Peptide, Dimer (6-6':9-9')-Bisdisulfide, Produced In Cho Cells, Glycoform Alfa in Optic Neuritis. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/mutated-human-immunoglobulin-g1-fc-fragment-anti-homo-sapiens-igg-receptor-fcrn-large-subunit-p51-neonatal-fc-receptorfcrn37-tyrmy3239-thrst3441-glute36218-lyshk213219-phenf214fc-fragment-of-human-immunoglobulin-heavy-constant-gamma-1-6-232-peptide-dimer-6-69-9-bisdisulfide-produced-in-cho-cells-glycoform-alfa-optic-neuritis

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →